$EBS
Emergent BioSolutions Inc. Stock $ebs

$ebs Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000136764422000024 Filed on February 25, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$723.2M	$1.793B	$583.0M
YoY Change	24.05%	15.26%	61.76%
Cost Of Revenue	$212.9M	$716.0M	$164.8M
YoY Change	29.19%	36.64%	24.1%
Gross Profit	$510.3M	$1.077B	$418.2M
YoY Change	22.02%	4.39%	437.53%
Gross Profit Margin	70.56%	60.06%	71.73%
Selling, General & Admin	$94.20M	$348.4M	$82.10M
YoY Change	14.74%	14.87%	13.71%
% of Gross Profit	18.46%	32.36%	19.63%
Research & Development	$83.00M	$234.0M	$59.50M
YoY Change	39.5%	-0.21%	-5.25%
% of Gross Profit	16.26%	21.73%	14.23%
Depreciation & Amortization	$29.20M	$62.20M	$28.90M
YoY Change	1.04%	24.15%	3.58%
% of Gross Profit	5.72%	5.78%	6.91%
Operating Expenses	$191.2M	$582.4M	$156.6M
YoY Change	22.09%	8.29%	4.54%
Operating Profit	$319.1M	$352.6M	$258.1M
YoY Change	23.63%	-18.72%	231.75%
Interest Expense	-$9.000M	$34.50M	-$8.700M
YoY Change	3.45%	10.22%	-4.4%
% of Operating Profit	-2.82%	9.78%	-3.37%
Other Income/Expense, Net	-$900.0K	-$38.20M	$3.400M
YoY Change	-126.47%	43.61%	17.24%
Pretax Income	$267.5M	$314.4M	$252.8M
YoY Change	5.81%	-22.79%	253.57%
Income Tax	$78.20M	$83.50M	$67.40M
% Of Pretax Income	29.23%	26.56%	26.66%
Net Earnings	$189.3M	$230.9M	$185.4M
YoY Change	2.1%	-24.32%	295.31%
Net Earnings / Revenue	26.18%	12.88%	31.8%
Basic Earnings Per Share		$4.32	$3.51
Diluted Earnings Per Share	$3.538M	$4.27	$3.44
COMMON SHARES
Basic Shares Outstanding	53.80M shares	53.50M shares	53.00M shares
Diluted Shares Outstanding		54.10M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$576.1M	$576.1M	$621.3M
YoY Change	-7.28%	-7.28%	270.26%
Cash & Equivalents	$576.1M	$576.1M	$621.3M
Short-Term Investments
Other Short-Term Assets	$70.50M	$70.50M	-$4.400M
YoY Change	-1702.27%	-1702.27%	-121.36%
Inventory	$350.8M	$350.8M	$307.0M
Prepaid Expenses
Receivables	$274.7M	$274.7M	$230.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.272B	$1.272B	$1.196B
YoY Change	6.37%	6.37%	74.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$800.1M	$828.4M	$644.1M
YoY Change	24.22%	22.71%	18.77%
Goodwill	$224.9M		$266.7M
YoY Change	-15.67%		0.04%
Intangibles	$604.6M		$663.1M
YoY Change	-8.82%		-6.99%
Long-Term Investments
YoY Change
Other Assets	$57.30M	$29.00M	$113.4M
YoY Change	-49.47%	-64.81%	25.58%
Total Long-Term Assets	$1.687B	$1.687B	$1.687B
YoY Change	-0.02%	-0.02%	2.82%
TOTAL ASSETS
Total Short-Term Assets	$1.272B	$1.272B	$1.196B
Total Long-Term Assets	$1.687B	$1.687B	$1.687B
Total Assets	$2.959B	$2.959B	$2.883B
YoY Change	2.63%	2.63%	23.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$128.9M	$128.9M	$136.1M
YoY Change	-5.29%	-5.29%	43.57%
Accrued Expenses	$51.70M	$146.2M	$46.90M
YoY Change	10.23%	6.79%	18.73%
Deferred Revenue	$11.70M		$44.60M
YoY Change	-73.77%		1251.52%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$31.60M	$31.60M	$33.80M
YoY Change	-6.51%	-6.51%	162.02%
Total Short-Term Liabilities	$373.8M	$373.8M	$384.5M
YoY Change	-2.78%	-2.78%	77.76%
LONG-TERM LIABILITIES
Long-Term Debt	$809.4M	$809.4M	$841.0M
YoY Change	-3.76%	-3.76%	5.34%
Other Long-Term Liabilities	$61.90M	$61.90M	$67.80M
YoY Change	-8.7%	-60.7%	39.51%
Total Long-Term Liabilities	$871.3M	$871.3M	$908.8M
YoY Change	-4.13%	-12.74%	7.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$373.8M	$373.8M	$384.5M
Total Long-Term Liabilities	$871.3M	$871.3M	$908.8M
Total Liabilities	$1.340B	$1.340B	$1.436B
YoY Change	-6.7%	-6.7%	15.93%
SHAREHOLDERS EQUITY
Retained Earnings	$957.8M		$726.9M
YoY Change	31.77%		72.33%
Common Stock	$100.0K		$100.0K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$152.2M		$39.60M
YoY Change	284.34%		0.0%
Treasury Stock Shares	3.800M shares		1.200M shares
Shareholders Equity	$1.619B	$1.619B	$1.447B
YoY Change
Total Liabilities & Shareholders Equity	$2.959B	$2.959B	$2.883B
YoY Change	2.63%	2.63%	23.89%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$189.3M	$230.9M	$185.4M
YoY Change	2.1%	-24.32%	295.31%
Depreciation, Depletion And Amortization	$29.20M	$62.20M	$28.90M
YoY Change	1.04%	24.15%	3.58%
Cash From Operating Activities	$329.0M	$321.1M	$245.1M
YoY Change	34.23%	-40.09%	100.74%
INVESTING ACTIVITIES
Capital Expenditures	-$46.70M	$225.0M	-$36.00M
YoY Change	29.72%	59.57%	-0.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$46.70M	-$225.0M	-$36.00M
YoY Change	29.72%	49.01%	-0.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$106.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-110.0M	-$141.0M	-2.300M
YoY Change	4682.61%	-302.88%	-96.03%
NET CHANGE
Cash From Operating Activities	329.0M	$321.1M	245.1M
Cash From Investing Activities	-46.70M	-$225.0M	-36.00M
Cash From Financing Activities	-110.0M	-$141.0M	-2.300M
Net Change In Cash	172.3M	-$45.20M	206.8M
YoY Change	-16.68%	-109.97%	635.94%
FREE CASH FLOW
Cash From Operating Activities	$329.0M	$321.1M	$245.1M
Capital Expenditures	-$46.70M	$225.0M	-$36.00M
Free Cash Flow	$375.7M	$96.10M	$281.1M
YoY Change	33.65%	-75.67%	77.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q3	ebs	Debt Instrument Covenant Net Leverage Ratio Adjustment Period DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod	P12M
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001367644
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021	dei	Entity File Number EntityFileNumber	001-33137
CY2020Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilities
CY2021Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilities
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Registrant Name EntityRegistrantName	EMERGENT BIOSOLUTIONS INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	14-1902018
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Professional Drive, Suite 400
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20879
CY2021	dei	City Area Code CityAreaCode	240
CY2021	dei	Local Phone Number LocalPhoneNumber	631-3200
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	EBS
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	3400000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50501421	shares
CY2021	us-gaap	Revenues Revenues	1792700000	USD
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	576100000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	621300000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	274700000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	230900000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	350800000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	307000000.0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	70300000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	36500000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1272100000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1195900000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	800100000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	644100000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	604600000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	663100000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	224900000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	266700000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57300000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	113400000	USD
CY2021Q4	us-gaap	Assets Assets	2959000000	USD
CY2020Q4	us-gaap	Assets Assets	2883200000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	128900000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	136100000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51700000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46900000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	88700000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	84600000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	31600000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	33800000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	72900000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	83100000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	373800000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	384500000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4500000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	34200000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	809400000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	841000000.0	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	94900000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	53200000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4700000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	55500000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	52700000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	67800000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	1340000000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1436200000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000.0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000.0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000.0	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000.0	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55100000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54300000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51300000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53100000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	100000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	100000	USD
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3800000	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1200000	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	152200000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	39600000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	829400000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	784900000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16100000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25300000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	957800000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	726900000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1619000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1447000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58700000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2959000000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2883200000	USD
CY2021	us-gaap	Revenues Revenues	1792700000	USD
CY2020	us-gaap	Revenues Revenues	1555400000	USD
CY2019	us-gaap	Revenues Revenues	1106000000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	234000000.0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	234500000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	226200000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	348400000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	303300000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	273500000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	41700000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58500000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59800000	USD
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1440100000	USD
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1121600000	USD
CY2019	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	991900000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	352600000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	433800000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	114100000	USD
CY2021	us-gaap	Interest Expense InterestExpense	34500000	USD
CY2020	us-gaap	Interest Expense InterestExpense	31300000	USD
CY2019	us-gaap	Interest Expense InterestExpense	38400000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3700000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4700000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1700000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38200000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26600000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36700000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	314400000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	407200000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	77400000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83500000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	102100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22900000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	54500000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.79
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.27
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.67
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53500000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52700000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51500000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54100000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53800000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52400000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	54500000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000000.0	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1700000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	400000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	6500000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-9400000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-1600000	USD
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-3700000	USD
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	4300000	USD
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	3200000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15400000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4400000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	240100000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	289700000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	50100000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	54500000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	42400000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	51000000.0	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	26700000	USD
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	123800000	USD
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	114500000	USD
CY2019	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	110700000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2900000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	31700000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	24800000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4100000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3500000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3000000.0	USD
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	41700000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	29000000.0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	12000000.0	USD
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	46900000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2400000	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1100000	USD
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	17200000	USD
CY2020	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2019	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000000.0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5200000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	200000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48200000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49000000.0	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8200000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	44000000.0	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	83200000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16700000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	24700000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29200000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	39100000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2500000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	19800000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16500000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9200000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	19400000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15100000	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4000000.0	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	21800000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4200000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-31800000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11200000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	16000000.0	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	321100000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	536000000.0	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	188000000.0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	225000000.0	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141000000.0	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86900000	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	0	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	10000000.0	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	10000000.0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-225000000.0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-151000000.0	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-96900000	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	106000000.0	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2020	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	130000000.0	USD
CY2021	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	450000000.0	USD
CY2019	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10600000	USD
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	373000000.0	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	105000000.0	USD
CY2021	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	25300000	USD
CY2020	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	14100000	USD
CY2019	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	11300000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	15900000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	31600000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8200000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13800000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13800000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7400000	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	8400000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1200000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2800000	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	50400000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-141000000.0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69500000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-35900000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-300000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000000.0	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	400000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45200000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	453500000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55600000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621500000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168000000.0	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112400000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	576300000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621500000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168000000.0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	30400000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	21000000.0	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	34500000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	71600000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	109300000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	30800000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	20000000.0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000000.0	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12300000	USD
CY2021	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	6600000	USD
CY2020	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	0	USD
CY2019	ebs	Noncash Purchases Of Treasury Stock NoncashPurchasesOfTreasuryStock	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	576100000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	621300000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167800000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	576300000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	621500000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168000000.0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1010900000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	27500000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	54500000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4400000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1088500000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	68800000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15400000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1447000000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	44500000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	USD
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	112600000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1619000000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Nature of the business and organization <div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (the "Company" or "Emergent") is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of eleven products (vaccines, therapeutics, and drug-device combination products) that contribute a substantial portion of its revenue. The Company has one product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company recently reorganized the structure of its business with a focus on markets and customers. As such, the key components of the business structure include a Government - Medical Countermeasures (MCM) business line, a Commercial business line and a Services line focused on CDMO. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government - MCM Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">AV7909</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA; and </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BioThrax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">ACAM2000</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BAT</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; and; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">CNJ-016</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Anthrasil</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">RSDL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas, and T-2 toxin.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Trobigard</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">NARCAN® (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; Recently, the Company licensed an authorized generic of naloxone nasal spray to Sandoz; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vaxchora</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">▪</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vivotif</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale. Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment.</span></div>
CY2021	ebs	Number Of Categories Of Public Health Threats NumberOfCategoriesOfPublicHealthThreats	5	category
CY2021	ebs	Number Of Revenue Generating Products NumberOfRevenueGeneratingProducts	11	product
CY2021	ebs	Number Of Product Candidates NumberOfProductCandidates	1	productCandidate
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements requires management to make estimates, judgments and assumptions that affect reported amounts and disclosures for asset impairments, revenue recognition, allowances for doubtful accounts, inventory, depreciation and amortization, business combinations, contingent consideration, stock-based compensation, income taxes, and other contingencies. Management continually re-evaluates its estimates, judgments and assumptions. These estimates are sometimes complex, sensitive to changes in assumptions and require fair value determinations using Level 3 fair value measurements. Actual results may differ materially from those estimates.
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Customers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has long-term contracts with the USG that expire at various times from 2022 through 2029. The Company has derived a significant portion of its revenue from sales of ACAM2000 and Anthrax Vaccines under contracts with the USG. The Company's current USG contracts do not necessarily increase the likelihood that it will secure future comparable contracts with the USG. The Company expects that a significant portion of the business will continue to be under government contracts that present a number of risks that are not typically present in the commercial contracting process. USG contracts for ACAM2000 and Anthrax Vaccines are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of ACAM2000 and Anthrax Vaccines to customers in addition to the USG, which would harm their growth opportunities. The Company's other product sales, largely Nasal Naloxone Products, are largely sold commercially through physician-directed or standing order prescriptions at retail pharmacies, as well as to state health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. Our CDMO customers are generally third-party pharmaceutical companies.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the Company seeks to expand its customer base and to renew its agreements with its customers prior to expiration of a contract, a delay in securing a renewal or a failure to secure a renewal or securing a renewal on less favorable terms may have a material adverse effect on the Company’s financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s accounts receivable do not represent a significant concentration of credit risk. The USG accounted for approximately 50%, 64% and 61% of total revenues for 2021, 2020 and 2019, respectively. The Company’s accounts receivable as of December 31, 2021 and 2020, consist primarily of amounts due from the USG or other large multi-national highly reputable customers for product sales, CDMO services or from government agencies under government grants. Management does not deem credit risk to be significant.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financial Institutions</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are maintained with several financial institutions. The Company has deposits held with banks that exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and, therefore, bear minimal credit risk.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Lender Counterparties</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is lender counterparty risk associated with the Company's revolving credit facility and derivatives instruments. There is risk that the Company’s revolving credit facility investors and derivative counterparties will not be available to fund as obligated. If funding under the revolving credit facility is unavailable, the Company may have to acquire a replacement credit facility from different counterparties at a higher cost or may be unable to find a suitable replacement. The Company seeks to manage risks from its revolving credit facility and derivative </span></div>instruments by contracting with experienced large financial institutions and monitoring the credit quality of its lenders. As of December 31, 2021, the Company does not anticipate nonperformance by any of its counterparties.
CY2021Q4	ebs	Number Of Stock Based Employee Compensation Plans NumberOfStockBasedEmployeeCompensationPlans	1	plan
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P7Y
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	In addition, during the year ended December 31, 2021, the Company revised its presentation on the consolidated statement of operations to separately present (i) lease revenue as opposed to combining with CDMO services revenues and (ii) cost of CDMO services as opposed to combining with cost of product sales. As the Company's lease revenue is solely associated with CDMO services and is substantially related to one arrangement which ended in 2021, the Company has combined the costs of CDMO services and leases on the consolidated statement of operations. All associated prior period amounts have been reclassified to conform to the current period presentation.
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Revenues Revenues	1792700000	USD
CY2020	us-gaap	Revenues Revenues	1555400000	USD
CY2019	us-gaap	Revenues Revenues	1106000000	USD
CY2021	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	62100000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1300000000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1300000000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	21500000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	41100000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	88900000	USD
CY2020	ebs	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	146200000	USD
CY2020	ebs	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	135000000.0	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	100100000	USD
CY2021	ebs	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	279700000	USD
CY2021	ebs	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	363400000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16400000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11700000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	44600000	USD
CY2020Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	172700000	USD
CY2021Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	224900000	USD
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	49800000	USD
CY2020Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	58200000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	274700000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	230900000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3200000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3100000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	352400000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	352200000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	37200000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	58100000	USD
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	6100000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	15000000.0	USD
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	43300000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	73100000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29200000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	31700000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	2800000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	58100000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2900000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	23800000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	37200000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	32700000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	23900000	USD
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	217500000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	160600000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	95800000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	102500000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	37500000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	43900000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	832100000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	350800000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	307000000.0	USD
CY2021	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	41500000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1119200000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	903200000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	319100000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	259100000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	800100000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	644100000	USD
CY2021	us-gaap	Depreciation Depreciation	62200000	USD
CY2020	us-gaap	Depreciation Depreciation	50100000	USD
CY2019	us-gaap	Depreciation Depreciation	49500000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	227500000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	604600000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	832100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	169000000.0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	663100000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58500000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	59800000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	58700000	USD
CY2021	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P11Y10M24D
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	55900000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	55800000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	55800000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	55800000	USD
CY2021Q4	ebs	Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter	381300000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	604600000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	29000000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	266700000	USD
CY2019Q4	us-gaap	Goodwill Gross GoodwillGross	266600000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	41700000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-100000	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	100000	USD
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	224900000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	266700000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	41700000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	41700000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	849600000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	885500000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	31600000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	33800000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8500000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	10700000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	809400000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	841000000.0	USD
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	2000000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1600000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	2000000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3500000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2020Q3	ebs	Debt Instrument Covenant Net Leverage Ratio Rolling Period DebtInstrumentCovenantNetLeverageRatioRollingPeriod	P12M
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	33800000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	363600000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	200000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2021Q4	ebs	Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter	452000000.0	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	849600000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021	ebs	Common Stock Number Of Votes Per Common Share CommonStockNumberOfVotesPerCommonShare	1	vote
CY2021Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	250000000	USD
CY2021Q4	ebs	Number Of Stock Based Employee Compensation Plans NumberOfStockBasedEmployeeCompensationPlans	1	plan
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y10M24D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.16
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.69
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15700000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38200000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5300000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	60700000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42400000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51000000.0	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26700000	USD
CY2020	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-19300000	USD
CY2020	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-3900000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15400000	USD
CY2021	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	4000000.0	USD
CY2021	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-5200000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	12000000.0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	2800000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-4400000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15400000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9200000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-19800000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-5300000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-900000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4400000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	0	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-3700000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	62800000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1400000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	14900000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27700000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11600000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	28400000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	14000000.0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	11000000.0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	39600000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	104500000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	24000000.0	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	38000000.0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1100000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1900000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4300000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1100000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1600000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3500000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-4100000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43900000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2400000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1100000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83500000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	102100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22900000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	7600000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	8100000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	3300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	3100000	USD
CY2021Q4	ebs	Deferred Tax Assets Tax Credit Carryforwards Scientific Research And Experimental Development DeferredTaxAssetsTaxCreditCarryforwardsScientificResearchAndExperimentalDevelopment	2100000	USD
CY2020Q4	ebs	Deferred Tax Assets Tax Credit Carryforwards Scientific Research And Experimental Development DeferredTaxAssetsTaxCreditCarryforwardsScientificResearchAndExperimentalDevelopment	8400000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8600000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	10200000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	36900000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	26200000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1700000	USD
CY2021Q4	ebs	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	6500000	USD
CY2020Q4	ebs	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	8200000	USD
CY2021Q4	ebs	Deferred Tax Assets Tax Deferred Expense Capitalized Costs DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts	3900000	USD
CY2020Q4	ebs	Deferred Tax Assets Tax Deferred Expense Capitalized Costs DeferredTaxAssetsTaxDeferredExpenseCapitalizedCosts	2300000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5600000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	65900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	124500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25000000.0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51100000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	40900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	73400000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	75100000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	54600000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	47600000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	50400000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6100000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	7700000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2800000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	4500000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	131600000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	117200000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	90700000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	43800000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	112000000.0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	362000000.0	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	63900000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	202400000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	45200000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	13500000	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	314400000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	407200000	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	77400000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	65800000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	85500000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	16300000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	16100000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	23200000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10300000	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-16800000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-7800000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-6900000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	1800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9200000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4300000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1500000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1000000.0	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4700000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	7600000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	3600000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-4900000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-7900000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2400000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	8300000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	800000	USD
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-700000	USD
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2300000	USD
CY2021	ebs	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	300000	USD
CY2020	ebs	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	6000000.0	USD
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.30
CY2019	ebs	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	4700000	USD
CY2021	ebs	Effective Income Tax Rate Reconciliation Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount	2900000	USD
CY2020	ebs	Effective Income Tax Rate Reconciliation Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount	2200000	USD
CY2019	ebs	Effective Income Tax Rate Reconciliation Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationCompensationLimitationAmount	1300000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	300000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-300000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1100000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	11400000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	5400000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	3600000	USD
CY2021	ebs	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	300000	USD
CY2020	ebs	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	-2600000	USD
CY2019	ebs	Effective Income Tax Rate Reconciliation Permanent Difference EffectiveIncomeTaxRateReconciliationPermanentDifference	-1800000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83500000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	102100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22900000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.27
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.27
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.25
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.25
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.30
CY2021Q4	ebs	Unrecognized Tax Benefits Noncurrent UnrecognizedTaxBenefitsNoncurrent	9800000	USD
CY2020Q4	ebs	Unrecognized Tax Benefits Noncurrent UnrecognizedTaxBenefitsNoncurrent	9200000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8800000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	500000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1500000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	400000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10400000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	600000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	400000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	200000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9800000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9800000	USD
CY2021	us-gaap	Pension Expense PensionExpense	2000000	USD
CY2020	us-gaap	Pension Expense PensionExpense	2400000	USD
CY2019	us-gaap	Pension Expense PensionExpense	1500000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	27600000	USD
CY2019Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	20600000	USD
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1400000	USD
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1400000	USD
CY2021	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	900000	USD
CY2020	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	800000	USD
CY2021	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	500000	USD
CY2020	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	6800000	USD
CY2021	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-100000	USD
CY2020	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	300000	USD
CY2021	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	0	USD
CY2020	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	4500000	USD
CY2021	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-1000000.0	USD
CY2020	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	2200000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	29300000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	27600000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	49200000	USD
CY2019Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	35200000	USD
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2400000	USD
CY2020	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1900000	USD
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	0	USD
CY2020	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	100000	USD
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	900000	USD
CY2020	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	800000	USD
CY2021	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	4600000	USD
CY2020	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-5000000.0	USD
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	500000	USD
CY2020	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	6800000	USD
CY2021	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	0	USD
CY2020	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	4500000	USD
CY2021	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-1600000	USD
CY2020	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	3900000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	46800000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	49200000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-17500000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-21600000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses After Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax	41800000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses After Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax	43000000.0	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	6600000	USD
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2400000	USD
CY2020	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1900000	USD
CY2019	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1300000	USD
CY2021	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	0	USD
CY2020	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	100000	USD
CY2019	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	200000	USD
CY2021	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	800000	USD
CY2020	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	600000	USD
CY2019	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	500000	USD
CY2021	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-600000	USD
CY2020	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-200000	USD
CY2019	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	0	USD
CY2021	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-200000	USD
CY2020	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-200000	USD
CY2019	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2021	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	0	USD
CY2020	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	-1000000.0	USD
CY2019	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1	-500000	USD
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	2000000.0	USD
CY2020	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	2400000	USD
CY2019	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	1500000	USD
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0030
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0002
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.030
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.030
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.014
CY2020	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.014
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	1400000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-5900000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-9900000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	-1300000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	-1000000.0	USD
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	4600000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	8900000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	2200000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	1700000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	1700000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	1800000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	1800000	USD
CY2021Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter	37600000	USD
CY2021Q4	ebs	Defined Benefit Plan Expected Future Benefit Payment DefinedBenefitPlanExpectedFutureBenefitPayment	46800000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	8900000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5100000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5600000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4500000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2700000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1300000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1100000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	600000	USD
CY2021	us-gaap	Lease Cost LeaseCost	6900000	USD
CY2020	us-gaap	Lease Cost LeaseCost	5600000	USD
CY2019	us-gaap	Lease Cost LeaseCost	3300000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	30000000.0	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	33200000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021	ebs	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P1Y
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6900000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6900000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3100000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	10400000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	34700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4700000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	30000000.0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	230900000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	305100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	54500000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53500000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52700000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51500000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	600000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1100000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	900000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54100000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53800000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52400000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.79
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.27
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.67
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000000.0	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	900000	shares
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	132000000	USD
CY2021	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P3Y
CY2021	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	110700000	USD
CY2020	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	108000000	USD
CY2019	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	51300000	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001367644-22-000024-index-headers.html	Edgar Link	pending
0001367644-22-000024-index.html	Edgar Link	pending
0001367644-22-000024.txt	Edgar Link	pending
0001367644-22-000024-xbrl.zip	Edgar Link	pending
a10-kexhibit212021.htm	Edgar Link	pending
a10-kexhibit212021001.jpg	Edgar Link	pending
a311-kramercert112.htm	Edgar Link	pending
a312-lindhalcert112.htm	Edgar Link	pending
a321-kramercert113.htm	Edgar Link	pending
a322-lindhalcert112.htm	Edgar Link	pending
ebs-20211231.htm	Edgar Link	pending
ebs-20211231.xsd	Edgar Link	pending
ebs-20211231_cal.xml	Edgar Link	unprocessable
ebs-20211231_def.xml	Edgar Link	unprocessable
ebs-20211231_g1.jpg	Edgar Link	pending
ebs-20211231_g10.jpg	Edgar Link	pending
ebs-20211231_g2.jpg	Edgar Link	pending
ebs-20211231_g3.jpg	Edgar Link	pending
ebs-20211231_g4.jpg	Edgar Link	pending
ebs-20211231_g5.jpg	Edgar Link	pending
ebs-20211231_g6.jpg	Edgar Link	pending
ebs-20211231_g7.jpg	Edgar Link	pending
ebs-20211231_g8.jpg	Edgar Link	pending
ebs-20211231_g9.jpg	Edgar Link	pending
ebs-20211231_htm.xml	Edgar Link	completed
ebs-20211231_lab.xml	Edgar Link	unprocessable
ebs-20211231_pre.xml	Edgar Link	unprocessable
ebshhso100201200004i_75a.htm	Edgar Link	pending
ebshhso100201200004i_75a001.jpg	Edgar Link	pending
ebshhso100201200004i_75a002.jpg	Edgar Link	pending
ebshhso100201200004i_75a003.jpg	Edgar Link	pending
emergentbiosolutions200-.htm	Edgar Link	pending
emergentbiosolutions200-001.jpg	Edgar Link	pending
emergentbiosolutions200-002.jpg	Edgar Link	pending
emergentbiosolutions200-003.jpg	Edgar Link	pending
emergentbiosolutions200-004.jpg	Edgar Link	pending
emergentbiosolutions70f0.htm	Edgar Link	pending
emergentbiosolutions70f0001.jpg	Edgar Link	pending
emergentbiosolutions70f0002.jpg	Edgar Link	pending
emergentbiosolutions70f0003.jpg	Edgar Link	pending
emergentbiosolutions70f0004.jpg	Edgar Link	pending
emergentbiosolutions70f0005.jpg	Edgar Link	pending
emergentbiosolutions75a5.htm	Edgar Link	pending
emergentbiosolutions75a5001.jpg	Edgar Link	pending
emergentbiosolutions75a5002.jpg	Edgar Link	pending
emergentbiosolutions75a5003.jpg	Edgar Link	pending
emergentbiosolutions75a5004.jpg	Edgar Link	pending
emergentbiosolutions77ea.htm	Edgar Link	pending
emergentbiosolutions77ea001.jpg	Edgar Link	pending
emergentbiosolutions77ea002.jpg	Edgar Link	pending
emergentbiosolutions77ea003.jpg	Edgar Link	pending
emergentbiosolutions77ea004.jpg	Edgar Link	pending
emergentbiosolutionsaa47.htm	Edgar Link	pending
emergentbiosolutionsaa47001.jpg	Edgar Link	pending
emergentbiosolutionsaa47002.jpg	Edgar Link	pending
emergentbiosolutionsaa47003.jpg	Edgar Link	pending
emergentbiosolutionsaa47004.jpg	Edgar Link	pending
emergentbiosolutionsadm-.htm	Edgar Link	pending
emergentbiosolutionsadm-001.jpg	Edgar Link	pending
emergentbiosolutionsadm-002.jpg	Edgar Link	pending
emergentbiosolutionsadm-003.jpg	Edgar Link	pending
emergentbiosolutionsadm-004.jpg	Edgar Link	pending
emergentbiosolutionsha65.htm	Edgar Link	pending
emergentbiosolutionsha65001.jpg	Edgar Link	pending
emergentbiosolutionsha65002.jpg	Edgar Link	pending
emergentbiosolutionsha65003.jpg	Edgar Link	pending
emergentbiosolutionsha65004.jpg	Edgar Link	pending
emergentbiosolutionshhso.htm	Edgar Link	pending
emergentbiosolutionshhso001.jpg	Edgar Link	pending
emergentbiosolutionshhso002.jpg	Edgar Link	pending
emergentbiosolutionshhso003.jpg	Edgar Link	pending
emergentbiosolutionsmodp.htm	Edgar Link	pending
emergentbiosolutionsmodp001.jpg	Edgar Link	pending
emergentbiosolutionsmodp002.jpg	Edgar Link	pending
emergentbiosolutionsmodp003.jpg	Edgar Link	pending
emergentbiosolutionsmodp004.jpg	Edgar Link	pending
ey10-kconsentv2.htm	Edgar Link	pending
ey10-kconsentv2001.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
registrationrightstermin.htm	Edgar Link	pending
registrationrightstermin001.jpg	Edgar Link	pending
registrationrightstermin002.jpg	Edgar Link	pending
registrationrightstermin003.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EBS
Emergent BioSolutions Inc. Stock $ebs

2021 Q4 Form 10-K Financial Statement

#000136764422000024 Filed on February 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EBS Emergent BioSolutions Inc. Stock $ebs

2021 Q4 Form 10-K Financial Statement

#000136764422000024 Filed on February 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EBS
Emergent BioSolutions Inc. Stock $ebs